Company news

Equillium, Inc. (NASDAQ:EQ) news

Equillium, Inc. news releases on 6ix. Latest, Oct 6, 2026: Equillium Announces Poster Presentation at the 50th Anniversary La Jolla Immunology Conference

Equillium, Inc. (NASDAQ:EQ) news

Press releases & updates

Equillium Announces Poster Presentation at the 50th Anniversary La Jolla Immunology Conference

Equillium Receives Australian Regulatory Clearance to Initiate First-in-Human Clinical Trial of EQ504

Equillium Receives Australian Regulatory Clearance to Initiate First-in-Human Clinical Trial of EQ504

Equillium Announces Poster Presentations at the 7th International AHR Conference

Equillium to Participate in Stifel’s 2026 Virtual Immunology and Inflammation Forum

Equillium Reports Second Quarter 2026 Financial Results and Recent Corporate Highlights

Equillium Reports Inducement Grants under Nasdaq Listing Rule 5635(4)

Equillium to Participate in the 2026 Jefferies Global Healthcare Conference

Equillium to Host Virtual Investor Event to Share New Insights into the Aryl Hydrocarbon Receptor (AhR) and miR-124 Axis

Equillium Reports First Quarter 2026 Financial Results and Corporate Highlights

Equillium to Participate in Oppenheimer’s 2026 Innovation on the Island Event

Equillium Announces Poster Presentations at IMMUNOLOGY2026™, the Annual Meeting of the American Association of Immunologists

Equillium Reports Fourth Quarter and Full Year 2025 Financial Results and Recent Corporate and Clinical Highlights

Equillium to Participate in the 38th Annual Roth Conference

Equillium Announces $35 Million Financing with RA Capital Management

Equillium to Participate in the Leerink Partners 2026 Global Healthcare Conference

Equillium Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Equillium to Participate in Upcoming Investor Conferences

Equillium Reports Third Quarter 2025 Financial Results and Provides Operational Update

Equillium to Host Ulcerative Colitis KOL Event on November 5, 2025

Equillium Announces Leadership and Corporate Updates

Equillium to Participate in the Cantor Global Healthcare Conference 2025

Equillium Announces Up to $50 Million Financing to Advance EQ504, a Novel Aryl Hydrocarbon Receptor Modulator, into the Clinic

Equillium Announces Strategic Expansion of Cryptocurrency Treasury Reserve Strategy

Equillium Announces Multiple Poster Presentations Highlighting EQ504 at the Annual Meeting of The American Association of Immunologists

Equillium Announces New Aryl Hydrocarbon Receptor Modulator Program EQ504

Equillium Announces Feedback from the U.S. Food and Drug Administration

Equillium Reports Fourth Quarter and Full Year 2024 Financial Results and Recent Corporate and Clinical Highlights

Equillium Announces Results of the Phase 3 EQUATOR Study of Itolizumab in First-Line Treatment of Patients with Acute Graft-Versus-Host Disease

Equillium Announces Positive Data from Phase 2 Study Evaluating Itolizumab in Patients with Moderate to Severe Ulcerative Colitis

Equillium to Present at the Stifel Healthcare Conference

Equillium Reports Third Quarter 2024 Financial Results and Provides Corporate and Clinical Updates

Equillium Announces Poster Presentation at the Society for Immunotherapy of Cancer

Equillium Maintains Rights to Itolizumab Following Ono Partnership

Equillium Announces Abstract Accepted for Poster Presentation at the Society for Immunotherapy of Cancer

Equillium to Present at the Stifel Virtual Inflammation & Immunology Summit

Equillium Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)

Equillium to Present at the Wells Fargo Healthcare Conference and the H.C. Wainwright 26th Annual Global Investor Conference

Equillium Reports Second Quarter 2024 Financial Results and Provides Recent Corporate and Clinical Highlights

Equillium Announces Positive Interim Analysis from Phase 3 EQUATOR Study of Itolizumab in Acute Graft-Versus-Host Disease

Equillium Announces Second Quarter 2024 Estimated Cash and Investments Balance

Equillium to be included in the Russell Microcap® Index

Equillium Announces Positive Topline Data from Phase 2 Study of EQ101 in Alopecia Areata

Equillium to Present at the Jefferies Global Healthcare Conference

Equillium Announces Interim Enrollment Achieved in Phase 3 EQUATOR Study of Itolizumab in Acute Graft-Versus-Host Disease

Equillium Reports First Quarter 2024 Financial Results and Provides Recent Clinical Highlights

Equillium Announces Poster Presentation at the Annual Meeting of The American Association of Immunologists

Equillium Announces Positive Topline Data from the Type B Portion of the Phase 1b EQUALISE Study of Itolizumab in Lupus Nephritis

Equillium Reports on Fourth Quarter and Full Year 2023 Financial Results and Corporate and Clinical Highlights

Equillium to Present at the H.C. Wainwright Autoimmune & Inflammatory Disease Conference and the LD Micro Invitational Conference